Cervical vagus nerve stimulation (VNS) has been widely accepted as adjunctive therapy for drug-resistant epilepsy and major depression. Its effects on glycemic control in humans were however poorly understood. The aim of our study was to investigate the potential effects of VNS on fasting blood glucose (FBG) in patients with drug-resistant epilepsy. Patients with drug-resistant epilepsy who had received VNS implants at the same hospital were retrospectively studied. Effects on FBG, weight, body mass index and blood pressure were evaluated at 4, 8 and 12 months of follow-up. 32 subjects (11 females/21 males, 19 ± 9 years, body mass index 22.2 ± 4.0 kg/m2) completed 12-month follow-up. At the 4 months, there were no significant changes in FBG concentrations from baseline to follow-up in both Sham-VNS (4.89 ± 0.54 vs. 4.56 ± 0.54 mmol/L, N = 13, p = 0.101) and VNS (4.80 ± 0.54 vs. 4.50 ± 0.56 mmol/L, N = 19, p = 0.117) groups. However, after 8 (4.90 ± 0.42 mmol/L, N = 32, p = 0.001) and 12 (4.86 ± 0.40 mmol/L, N = 32, p = 0.002) months of VNS, FBG levels significantly increased compared to baseline values (4.52 ± 0.54 mmol/L, N = 32). Changes in FBG concentrations at both 8 (R2 = 0.502, N = 32, p < 0.001) and 12 (R2 = 0.572, N = 32, p < 0.001) months were negatively correlated with baseline FBG levels. Our study suggests that chronic cervical VNS elevates FBG levels with commonly used stimulation parameters in patients with epilepsy. Trial registration VNSRE, NCT02378792. Registered 4 March 2015—Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02378792

中文翻译：

---

耐药性癫痫的慢性迷走神经刺激可能会影响空腹血糖浓度。

宫颈迷走神经刺激（VNS）已被广泛接受为耐药性癫痫和重度抑郁的辅助治疗。然而，其对人类血糖控制的作用知之甚少。我们的研究目的是研究VNS对耐药性癫痫患者空腹血糖（FBG）的潜在影响。回顾性研究在同一家医院接受过VNS植入的耐药性癫痫患者。在随访的第4、8和12个月评估了对FBG，体重，体重指数和血压的影响。32名受试者（11名女性/ 21名男性，19±9岁，体重指数22.2±4.0 kg / m2）完成了12个月的随访。在两个月内，两个Sham-VNS的FBG浓度从基线到随访均无明显变化（4.89±0.54 vs. 4.56±0.54 mmol / L，N = 13）。p = 0.101）和VNS（4.80±0.54 vs.4.50±0.56 mmol / L，N = 19，p = 0.117）组。但是，在8个月（4.90±0.42 mmol / L，N = 32，p = 0.001）和12（4.86±0.40 mmol / L，N = 32，p = 0.002）VNS后，与基线值相比，FBG水平显着增加（4.52±0.54mmol / L，N ＝ 32）。FBG浓度在8个月（R2 = 0.502，N = 32，p <0.001）和12个月（R2 = 0.572，N = 32，p <0.001）的变化与基线FBG水平呈负相关。我们的研究表明，慢性宫颈VNS通过癫痫患者常用的刺激参数提高FBG水平。VNSRE试用注册，NCT02378792。2015年3月4日注册-追溯注册，https：//clinicaltrials.gov/ct2/show/NCT02378792 N = 32，p = 0.001）和12（4.86±0.40 mmol / L，N = 32，p = 0.002）个月的VNS，FBG水平明显高于基线值（4.52±0.54 mmol / L，N = 32） 。FBG浓度在8个月（R2 = 0.502，N = 32，p <0.001）和12个月（R2 = 0.572，N = 32，p <0.001）的变化与基线FBG水平呈负相关。我们的研究表明，慢性宫颈VNS通过癫痫患者常用的刺激参数提高FBG水平。VNSRE试用注册，NCT02378792。2015年3月4日注册-追溯注册，https：//clinicaltrials.gov/ct2/show/NCT02378792 N = 32，p = 0.001）和12（4.86±0.40 mmol / L，N = 32，p = 0.002）个月的VNS，FBG水平明显高于基线值（4.52±0.54 mmol / L，N = 32） 。FBG浓度在8个月（R2 = 0.502，N = 32，p <0.001）和12个月（R2 = 0.572，N = 32，p <0.001）的变化与基线FBG水平呈负相关。我们的研究表明，慢性宫颈VNS通过癫痫患者常用的刺激参数提高FBG水平。VNSRE试用注册，NCT02378792。2015年3月4日注册-追溯注册，https：//clinicaltrials.gov/ct2/show/NCT02378792 p <0.001）和12（R2 = 0.572，N = 32，p <0.001）月与基线FBG水平呈负相关。我们的研究表明，慢性宫颈VNS通过癫痫患者常用的刺激参数提高FBG水平。VNSRE试用注册，NCT02378792。2015年3月4日注册-追溯注册，https：//clinicaltrials.gov/ct2/show/NCT02378792 p <0.001）和12（R2 = 0.572，N = 32，p <0.001）月与基线FBG水平呈负相关。我们的研究表明，慢性宫颈VNS通过癫痫患者常用的刺激参数提高FBG水平。VNSRE试用注册，NCT02378792。2015年3月4日注册-追溯注册，https：//clinicaltrials.gov/ct2/show/NCT02378792